Atyr Pharma To Participate In April Investor Conferences

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025.

Details of the conferences appear below:

Conference: Jones Healthcare and Technology Innovation Conference
Date: April 8 – 9, 2025
Location: Las Vegas, NV
Format: 1x1 Investor Meetings

Conference: Piper Sandler Spring Biopharma Symposium
Date: April 17, 2025
Location: Boston, MA
Format: 1x1 Investor Meetings

For more information on how to register, please contact your Jones or Piper Sandler representative.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

Frequently Asked Questions

What is aTyr Pharma?

aTyr Pharma is a clinical-stage biotechnology company developing first-in-class medicines from its proprietary tRNA synthetase platform, focusing on fibrosis and inflammation treatments.

What is efzofitimod?

Efzofitimod is aTyr's lead therapeutic candidate, a first-in-class biologic immunomodulator in clinical development for interstitial lung disease.

Where can I learn more?

Visit www.atyrpharma.com for more information about aTyr Pharma and its research.

First published on Fri, Apr 4, 2025

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

aTyr Pharma efzofitimod tRNA synthetase biotechnology fibrosis inflammation interstitial lung disease investor conference clinical stage

Join The Discussion

- Promoted By TechDogs -

Biotechnology